NRT.AX - Kazia Therapeutics Limited

ASX - ASX Delayed Price. Currency in AUD
0.39
0.00 (0.00%)
As of 3:48PM AEDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.39
Open0.39
Bid0.34 x 764400
Ask0.40 x 1559400
Day's Range0.39 - 0.39
52 Week Range0.34 - 1.05
Volume630
Avg. Volume60,970
Market Cap18.848M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.23
Earnings DateFeb 23, 2016 - Feb 27, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.22
  • ACCESSWIRE4 months ago

    Edison Issues ADR Update on Novogen (NVGN)

    LONDON, UK / ACCESSWIRE / September 11, 2017 / Novogen (NASDAQ: NVGN) is on track to commence a Phase II trial of GDC-0084 in glioblastoma in Q4 CY17, in line with previous guidance. It plans to meet with ...

  • PR Newswire5 months ago

    Australian cancer specialists may hold key to next advancement in ovarian cancer treatment

    SYDNEY, Aug. 30, 2017 /PRNewswire/ -- Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy. Flinders Medical Centre in South Australia and Westmead Hospital in Sydney are also participating, along with leading US hospitals Peggy and Charles Stephenson Cancer Centre, and Mary Crowley Cancer Research Centre. "We've seen massive developments in other types of cancer but ovarian cancer has remained a challenge and, despite it being an unforgiving disease for women, treatment options have fallen behind as money and research are focused elsewhere," Associate Professor Coward said.

  • PR Newswire5 months ago

    GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in October 2016, after completion of a phase I clinical trial in advanced glioma.

  • PR Newswire5 months ago

    GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc in October 2016, after completion of a phase I clinical trial in advanced glioma.

  • PR Newswire5 months ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire5 months ago

    Board Review of Business Operations and Governance

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on a review of business operations recently completed by the Board and management team. The review was initiated following appointment of Iain Ross as Chairman on 8 June 2017, and has involved an extensive process of consultation with shareholders and investors.

  • PR Newswire5 months ago

    Progress Update on Cantrixil(TM) (TRXE-002-1) Development

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Novogen commenced a phase I clinical trial of Cantrixil in ovarian cancer in December 2016.

  • PR Newswire5 months ago

    Progress Update on Cantrixil(TM) (TRXE-002-1) Development

    NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Novogen commenced a phase I clinical trial of Cantrixil in ovarian cancer in December 2016.

  • Benzinga10 months ago

    Novogen Receives $4.4M R&D Tax Rebate

    Novogen Ltd (NASDAQ: NVGN ) is pleased to confirm receipt of $4.4m from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2016. These funds will be ...

  • PR Newswire10 months ago

    Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

    - Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC ...

  • PR Newswire10 months ago

    Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

    - Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC ...

  • PR Newswire10 months ago

    Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

    Funds will be applied to development of a next-generation anti-tropomyosin program, intended to provide potential new therapies for cancer. NASDAQ: NVGN) is pleased to announce that it has been awarded a grant of up to A$3m over three years under the Cooperative Research Centre Project (CRC-P) scheme managed by the Australian Department of Industry Innovation and Science (DIIS). The grant has been awarded to fund development of a next-generation anti-tropomyosin program, which is intended to provide potential new therapies for cancer.

  • PR Newswire10 months ago

    Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

    Funds will be applied to development of a next-generation anti-tropomyosin program, intended to provide potential new therapies for cancer. NASDAQ: NVGN) is pleased to announce that it has been awarded a grant of up to A$3m over three years under the Cooperative Research Centre Project (CRC-P) scheme managed by the Australian Department of Industry Innovation and Science (DIIS).